MOHAP approves first oral GLP-1 pill for UAE's 32% obesity rate, May 2026 launch

MOHAP has approved the UAE's first oral obesity drug, a pill-based GLP-1 receptor agonist set to reach pharmacies and clinics from May 2026. The approval breaks the injectable monopoly on GLP-1 weight management treatments in the Emirates at a time when 32% of UAE adults are classified as obese.

Why a pill changes the market calculus

Injectable GLP-1 drugs, including semaglutide (Wegovy) and tirzepatide (Zepbound), have dominated the UAE's weight management market since 2023. But patient uptake has been limited by two factors: needle aversion and chronic supply shortages that forced Dubai and Abu Dhabi clinics to maintain waiting lists through much of 2025. An oral formulation removes the first barrier and, if manufacturing scales, could ease the second.

The World Health Organization puts UAE adult obesity at 32%, climbing to 37% among Emirati nationals. The International Diabetes Federation ranks the UAE 15th globally for diabetes prevalence at 16.3% of the adult population, a condition closely linked to obesity. The weight management market across the Emirates is now worth an estimated AED 2.8 billion annually.

Regulatory and reimbursement implications

MOHAP's approval applies across all seven emirates, though Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DOH) each run their own formulary and pricing review processes. Operators should expect a lag of four to eight weeks between MOHAP registration and inclusion on emirate-level insurance formularies.

Reimbursement is the question that will determine adoption speed. Injectable GLP-1s sit in a grey zone: covered by some insurers for diabetic patients but classified as elective for weight management alone. An oral formulation prescribed by a licensed endocrinologist or bariatric specialist could push insurers toward broader coverage, particularly if MOHAP classifies obesity as a chronic disease indication rather than a cosmetic concern.

DHA issued guidance in late 2025 requiring facilities prescribing weight-loss medications to maintain a multidisciplinary team that includes a dietitian and psychologist. That rule applies to the new oral treatment. Clinics without the required team structure will not be eligible to prescribe.

What operators should watch

• Formulary inclusion timelines: Track DHA and DOH formulary updates in May and June for insurance coverage status and approved price points
• Prescribing restrictions: Confirm whether MOHAP limits prescribing authority to specialists or extends it to general practitioners
• Supply allocation: Early supply will likely be constrained; hospital pharmacies and large chains with direct distributor relationships will have first access
• Patient volume impact: Clinics with existing bariatric and endocrinology programmes should prepare for increased consultations as patient demand shifts from injectable to oral options

The UAE's obesity drug market has grown 41% year-on-year since 2023, driven almost entirely by GLP-1 injectables. An oral alternative available from May could accelerate that growth by converting patients who have resisted injection-based treatment. Healthcare operators across the Emirates now face a staffing and capacity question: the demand is already here, and the easier dosing format will widen it.